



**UNICHEM**  
**LABORATORIES LTD.**

Fax No : 91 (22) 2678 4391 / 5198  
Tel. No. : 91 (22) 66888333  
Website : <http://www.unichemlabs.com>  
CIN : L99999MH1962PLC012451.

**Registered & Corporate Office :** Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

July 4, 2018

**Department of Corporate Services**  
Bombay Stock Exchange,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001.

**Mr. Hari K.**  
Asst. Vice President - Operations  
National Stock Exchange of India Ltd.  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai - 400 051.

**Ref: BSE Scrip Code - 506690 : NSE Symbol - UNICHEMLAB**

Dear Sir,

**Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release pertaining to receipt of ANDA approval from USFDA for Unichem's Montelukast Chewable Tablets, 4 mg and 5 mg.

**For Unichem Laboratories Limited**

*N. S. Thakore*

Neema Thakore

Head- Legal & Company Secretary





**UNICHEM  
LABORATORIES LTD.**

Fax No : 91 (22) 2678 4391 / 5198  
Tel. No. : 91 (22) 66888333  
Website : <http://www.unichemlabs.com>  
CIN : L99999MH1962PLC012451.

**Registered & Corporate Office :** Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

Mumbai, Wednesday July 4, 2018

### PRESS RELEASE

Unichem Laboratories Limited is pleased to announce that it has received final ANDA approval for its Montelukast Chewable Tablets, 4 mg and 5 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Merck Sharp & Dohme Corporation's Singulair® Tablets, 4 mg and 5 mg.

Unichem's Montelukast Chewable Tablets, 4 mg and 5 mg are the AB rated generic equivalent of Merck Sharp & Dohme Corporation's Singulair® Tablets, 4 mg and 5 mg. They are indicated for:

- the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older;
- the prevention of exercise-induced broncho constriction in patients 15 years of age and older and
- the relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 6 months of age and older).

The Product will be commercialized from Unichem's Goa Plant.

#### **About Unichem Laboratories Limited**

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world. In India, The Company has strong skills in product development, process chemistry and manufacturing complex API as well as dosage forms. More information about the Company can be found at [www.unichemlabs.com](http://www.unichemlabs.com)

#### **For more information please contact:**

Ms. Neema Thakore  
Ph: +91-22-66888 404  
E-mail: [neema.thakore@unichemlabs.com](mailto:neema.thakore@unichemlabs.com)

Mr. Rakesh Parikh  
Ph: +91-22-66888 414  
E-mail: [rparikh@unichemlabs.com](mailto:rparikh@unichemlabs.com)



#### **Disclaimer:**

*This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ serially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.*